Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Moodys
Merck
Boehringer Ingelheim
AstraZeneca

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

HALOG-E Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Halog-e, and what generic alternatives are available?

Halog-e is a drug marketed by Sun Pharm Inds Inc and is included in one NDA.

The generic ingredient in HALOG-E is halcinonide. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the halcinonide profile page.

Summary for HALOG-E
US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: 48
Patent Applications: 4,978
DailyMed Link:HALOG-E at DailyMed
Drug patent expirations by year for HALOG-E
Synonyms for HALOG-E
(11?,16?)-21-Chloro-9-fluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregn-4-ene-3,20-dione
(11|A,16|A)-21-Chloro-9-fluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregn-4-ene-3,20-dione
(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS)-6b-(chloroacetyl)-4b-fluoro-5-hydroxy-4a,6a,8,8-tetramethyl-3,4,4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-tetradecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
093H354
21-Chloro-9-fluoro-11beta,16alpha,17-trihydroxypregn-4-ene-3,20-dione cyclic 16,17-acetal with acetone
3093-35-4
5-19-06-00301 (Beilstein Handbook Reference)
AC-1114
AC-1774
AC1L9FG3
Adcortin
AKOS015962797
Alcinonide
AN-14636
Ascochrom
BC214763
Betacorton
BPBio1_000759
BRD-K81709173-001-03-8
BRN 1358242
BSPBio_000689
C24H32ClFO5
CAS-3093-35-4
CCG-220655
CHEBI:31663
CHEMBL1200845
D01308
DB06786
DSSTox_CID_25375
DSSTox_GSID_45375
DSSTox_RID_80836
DTXSID6045375
EINECS 221-439-6
Halciderm
Halcimat
Halcinonid
Halcinonida
Halcinonida [INN-Spanish]
halcinonide
Halcinonide (JAN/USP/INN)
Halcinonide [USAN:USP:INN:BAN:JAN]
Halcinonide, United States Pharmacopeia (USP) Reference Standard
Halcinonidum
Halcinonidum [INN-Latin]
Halcort
Halog
Halog (TN)
HMS1570C11
HMS2097C11
HMS2230O07
HMS3714C11
HY-B0877
MLS002153935
MolPort-005-937-976
NCGC00016621-01
NCGC00179475-01
NCGC00179475-03
P753
Pregn-4-ene-3,20-dione, 21-chloro-9-fluoro-11-beta,16-alpha,17-trihydroxy-, cyclic16,17-acetal with acetone
Pregn-4-ene-3,20-dione, 21-chloro-9-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-
Prestwick_1069
Prestwick0_000655
Prestwick1_000655
Prestwick2_000655
Prestwick3_000655
Q-201180
s4098
SC-80633
SCHEMBL4335
SI86V6QNEG
SMR001233277
SO-18566
SPBio_002610
SQ 18566
SQ-18,566
SQ-18566
Tox21_110530
Tox21_110530_1
UNII-SI86V6QNEG
Volog
ZINC4213474

US Patents and Regulatory Information for HALOG-E

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Inc HALOG-E halcinonide CREAM;TOPICAL 018234-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Baxter
Express Scripts
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.